期刊文献+

胃癌靶向药物治疗进展 被引量:8

Gastric cancer targeted drug therapy
下载PDF
导出
摘要 胃癌是消化系统常见的恶性肿瘤之一,由于早诊率低,大多数患者在诊断时已经处于疾病中晚期。化疗是进展期胃癌的重要治疗方法,但是,细胞毒性药物联合方案并没有从根本上提高化疗有效率。分子靶向治疗是近年来在治疗血液系统肿瘤和实体瘤中涌现出的新治疗手段。随着对胃癌发生、发展和转移过程中分子生物学机制的研究,这种治疗手段也逐步应用于胃癌治疗的临床实践。这些靶向治疗策略主要包括:HER2单克隆抗体,表皮生长因子受体抑制剂,血管生成抑制剂,多靶点酪氨酸激酶抑制剂,细胞周期蛋白依赖性激酶(CDKs),mTOR抑制剂,c-Met抑制剂,基质金属蛋白酶抑制剂,IGF-1R抑制剂,HSP90抑制剂等。本文就进展期胃癌近年来分子靶向治疗的研究结果及相关进展作一综述。 Gastric cancer is one of the most common malignancies in the digestive system. Due to the low rate of diagnosis, most of the patients with gastric cancer have advanced disease at the time of diagnosis. Chemotherapy is still the mainstay of treatment for advanced gastric cancer, but efficacy of combination chemotherapy is modest. Novel treatment options are urgently needed to improve the outcome of patients with advanced gastric cancer. Molecular targeted therapies have emerged as a novel approach to the treatment of both hematological and solid tumors in recent years. The study of molecular biological mechanisms underlying the formation, progression and metastasis in advanced gastric cancer has enabled us to use the new approach to treat this disease in clinical practice. These therapeutic strategies include targeting EGFR signal transduction pathway, HER2 monoclonal antibody, anti-angiogenesis, multityrosine kinase inhibitors, cyclin dependent kinase (CDK) inhibitors c-Met inhibitors, PI3k/Akt/mTOR pathway inhibitors, Matrix metalloproteinase, IGF-1R inhibitors, and HSP 90 inhibitors. The aim of this review is to summarize the most recent publications on targeted therapies in advanced gastric cancer.
作者 邓薇 沈琳
出处 《中国医学前沿杂志(电子版)》 2013年第1期29-41,共13页 Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词 胃癌 曲妥珠单抗 贝伐单抗 西妥昔单抗 多靶点酪氨酸激酶抑制剂 Favopiridol RAD001 Figitumumab 17-AAG Foretinib Gastric cancer Trastuzumab Bevacizumab Cetuximab Multityrosine kinase inhibitors Favopiridol RAD001 Figitumumab 17-AAG Foretinib
  • 相关文献

参考文献5

二级参考文献34

  • 1Gen Tamura.Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer[J].World Journal of Gastroenterology,2006,12(2):192-198. 被引量:107
  • 2中国慢性胃炎共识意见[J].胃肠病学,2006,11(11):674-684. 被引量:835
  • 3Shia J,Klimstra DS,Li AR,et al.Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma:an immunohistochemical and chromogenic in situ hybridization study[J].Mod Pathol,2005,18:1350-1356.
  • 4Kim MA,Lee HS,Lee HE,et al.EGFR in gastric carcinomas:prognostic significance of protein overexpression and high gene copy number[J].Histopathology,2008,52:738-746.
  • 5Yamada A,Saito N,Kameoka S,et al.Clinical significance of epidermal growth factor(EGF) expression in gastric cancer[J].Hepatogastroenterology,2007,54:1049-1052.
  • 6Celikel C,Eren F,Gulluoglu B,et al.Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas:prognostic implications[J].Pathol Oncol Res,2007,13:215-226.
  • 7Pino MS,Shrader M,Baker CH,et al.Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib(iressa) in human pancreatic cancer cell lines[J].Cancer Res,2006,66:3802-3812.
  • 8Karapetis CS,Khambata-Ford S,Jonker DJ,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J].N Engl J Med,2008,359:1757-1765.
  • 9Lee KH,Lee JS,Suh C,et al.Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer.An analysis of 140 cases[J].Cancer,1995,75:2794-2801.
  • 10Han S,Park SR,Lee K,et al.Phase Ⅱ study and biomarker analysis of cetuximab in combination with oxaliplatin,5-fluorouracil,leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer[J].J Clin Oncol,2008,26:a4549.

共引文献35

同被引文献61

  • 1庞蓓蓓,周毅,龙浩成,陶德定,胡俊波,龚建平.胃肠道肿瘤细胞周期素A的表达及其与化疗药物敏感性的关系[J].华中科技大学学报(医学版),2007,36(4):521-524. 被引量:2
  • 2Bijnsdorp IV, Kruyt FA, Fukushima M, et al. Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growthfactor receptor inhibitor erlotinib in human colorectal cancer cell lines[ J]. Cancer Sci, 2010,101 (2) :440 - 447.
  • 3Tabemero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration [ J ] ? Oncologist, 2008,13(2) :113 - 119.
  • 4De Reyni~s A, Boige V, Milano G, et al. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response sig- nature [ J ]. J Clin Oncol, 2008,26 ( 13 ) :2228 - 2230.
  • 5Tabernero J, Van Cutsem E, Dlaz - Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leueovorin, and oxaliplatin in the first - line treatment of metastatic eolorectal cancer [ J ]. J Clin Oneol, 2007,25 ( 33 ) :5225 - 5232.
  • 6张爱群,付红霞,孙富国,李金生,周爱玲,王学民,柯小宁.Cyclin A与P21蛋白在子宫腺肌病中的表达及临床意义[J].河北医药,2007,29(11):1163-1165. 被引量:5
  • 7Rocha - Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumorst[ J ]. Cancer Control,2007,14 ( 3 ) : 295.
  • 8Wolff AC, Hammond ME, Schwartz JN, et ai. American society of clinical oncology/college of American pathologists guideline recom- mendations for human epidermal growth factor receptor 2 testing in breast cancer[ J ]. J Clin Onco1,2007,25 ( 1 ) : 118 - 145.
  • 9Liakakos T, Fatourou E, Ziogas D. Targeting VEGF, EGFR, and other interacting pathways for gastric cancer promises and reality [ J ]. Ann Surg Oncol,2008,15 ( 10 ) :2981 - 2982.
  • 10Lieto E, Ferraraccio F, Orditura M. Expression of vascular endo- thelial growth factor(VEGF) and epidermal growth factor receptor(EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients[ J ]. Ann Surg Oncol,2008,15 (1) :69 -79.

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部